Skip to main content

Table 3 SPM risk associated with combined FAS/FASL variant genotypes after index OPC and non-OPC

From: Site disparities in apoptotic variants as predictors of risk for second primary malignancy in patients with squamous cell carcinoma of the head and neck

No. variant genotypes

OPC

Non-OPC

cHRsa (95 % CI), P

aHRs (95 % CI)b, P

SPM/SPM-free (42/710)

SPM/SPM-free

(n = 82/695)

OPC

Non-OPC

OPC

Non-OPC

 0-1 (ref.)

5/142

10/132

1.0

1.0

1.0

1.0

 2

15/256

27/264

1.3 (0.4–3.5), 0.673

1.4 (0.6–2.7), 0.585

1.3 (0.5–3.7), 0.698

1.5 (0.5–3.3), 0.612

 3

16/220

31/229

1.6 (0.6–4.1), 0.587

1.8 (0.9–3.5), 0.061

1.7 (0.5–3.8), 0.632

1.8 (1.0–3.9), 0.051

 4

6/92

14/70

2.2 (0.9–6.8), 0.112

2.7 (1.2–6.1), 0.014

2.0 (0.9–6.6), 0.110

2.2 (1.2–6.5), 0.021

  1. aCrude HRs
  2. bHRs were adjusted for age, sex, ethnicity, smoking, alcohol, index cancer stage, and treatment